Literature DB >> 33069729

Targeting the Jak/Signal Transducer and Activator of Transcription 3 Pathway with Ruxolitinib in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa-Squamous Cell Carcinoma.

Joanna Jacków1, Avina Rami2, Ryota Hayashi2, Corey Hansen2, Zongyou Guo2, Dominick DeLorenzo2, Alberto Pappalardo2, David Alvarez Cespedes2, Arianna L Kim2, Rolando Perez-Lorenzo2, David M Owens2, Angela M Christiano3.   

Abstract

Entities:  

Year:  2020        PMID： 33069729     DOI： 10.1016/j.jid.2020.08.022

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  3 in total

Review 1.  Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature.

Authors:  Domenico Bonamonte; Angela Filoni; Aurora De Marco; Lucia Lospalluti; Eleonora Nacchiero; Valentina Ronghi; Anna Colagrande; Giuseppe Giudice; Gerardo Cazzato
Journal:  Cells       Date:  2022-04-17       Impact factor: 7.666

Review 2.  Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Grace Tartaglia; Qingqing Cao; Zachary M Padron; Andrew P South
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

3.  Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.

Authors:  Susan J Robertson; Elizabeth Orrin; Manpreet K Lakhan; Gavin O'Sullivan; Jessie Felton; Alistair Robson; Danielle T Greenblatt; Catina Bernardis; John A McGrath; Anna E Martinez; Jemima E Mellerio
Journal:  Acta Derm Venereol       Date:  2021-08-24       Impact factor: 3.875
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.